Literature DB >> 28762137

A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.

Adepitan A Owosho1,2, Cherry L Estilo2, Joseph M Huryn2, Ping Chi3,4, Cristina R Antonescu5.   

Abstract

Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997-2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.

Entities:  

Keywords:  H3K27me3; Malignant peripheral nerve sheath tumor; NF1; Polycomb repressor complex 2

Mesh:

Substances:

Year:  2017        PMID: 28762137      PMCID: PMC5953865          DOI: 10.1007/s12105-017-0841-y

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  41 in total

1.  Malignant peripheral nerve sheath tumours in the head and neck region: retrospective analysis of clinicopathological features and treatment outcomes.

Authors:  C Ma; A Ow; O H Shan; Y Wu; C Zhang; J Sun; T Ji; L Pingarron Martin; L Wang
Journal:  Int J Oral Maxillofac Surg       Date:  2014-03-28       Impact factor: 2.789

2.  Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.

Authors:  Jennifer LaFemina; Li-Xuan Qin; Nicole H Moraco; Cristina R Antonescu; Ryan C Fields; Aimee M Crago; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

3.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

Authors:  Thomas De Raedt; Eline Beert; Eric Pasmant; Armelle Luscan; Hilde Brems; Nicolas Ortonne; Kristian Helin; Jason L Hornick; Victor Mautner; Hildegard Kehrer-Sawatzki; Wade Clapp; James Bradner; Michel Vidaud; Meena Upadhyaya; Eric Legius; Karen Cichowski
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

4.  Methylation-based classification of benign and malignant peripheral nerve sheath tumors.

Authors:  Manuel Röhrich; Christian Koelsche; Daniel Schrimpf; David Capper; Felix Sahm; Annekathrin Kratz; Jana Reuss; Volker Hovestadt; David T W Jones; Melanie Bewerunge-Hudler; Albert Becker; Joachim Weis; Christian Mawrin; Michel Mittelbronn; Arie Perry; Victor-Felix Mautner; Gunhild Mechtersheimer; Christian Hartmann; Ali Fuat Okuducu; Mirko Arp; Marcel Seiz-Rosenhagen; Daniel Hänggi; Stefanie Heim; Werner Paulus; Jens Schittenhelm; Rezvan Ahmadi; Christel Herold-Mende; Andreas Unterberg; Stefan M Pfister; Andreas von Deimling; David E Reuss
Journal:  Acta Neuropathol       Date:  2016-02-08       Impact factor: 17.088

Review 5.  Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.

Authors:  Amir Minovi; Oliver Basten; Ben Hunter; Wolfgang Draf; Ulrike Bockmühl
Journal:  Head Neck       Date:  2007-05       Impact factor: 3.147

6.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

7.  Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  J Cutan Pathol       Date:  2008-06-10       Impact factor: 1.587

8.  Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.

Authors:  Carlos N Prieto-Granada; Thomas Wiesner; Jane L Messina; Achim A Jungbluth; Ping Chi; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

9.  Sox10: a pan-schwannian and melanocytic marker.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  Am J Surg Pathol       Date:  2008-09       Impact factor: 6.394

10.  Malignant peripheral nerve sheath tumors of the head and neck: Demographics, clinicopathologic features, management, and treatment outcomes.

Authors:  Armin Arshi; Bobby A Tajudeen; Maie St John
Journal:  Oral Oncol       Date:  2015-10-09       Impact factor: 5.337

View more
  4 in total

1.  Mixed malignant peripheral nerve sheath tumor in the inguinal region: a case report.

Authors:  Mengyao Liu; Shuaichen Liu; Jinping Zhan; Weiyi Chen; Ping Yang; Huihui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

2.  Tongue Schwannoma: A Clinicopathologic Study of 19 Cases.

Authors:  Lester D R Thompson; Stephen S Koh; Sean K Lau
Journal:  Head Neck Pathol       Date:  2019-09-04

3.  High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors.

Authors:  Ning Zhang; Zhi Zeng; Shaobo Li; Fei Wang; Peng Huang
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

4.  Malignant peripheral nerve sheath tumors of the sino-nasal tract: about an unusual case report.

Authors:  Ismail Boujida; Hafsa Elouazzani; Sabrine Derqaoui; Hicham Belghiti; Zahra Sayad; Malik Boulaades; Fouad Zouaidia; Nadia Cherradi
Journal:  J Surg Case Rep       Date:  2022-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.